earnings
confidence high
sentiment neutral
materiality 0.65
Ensysce Q1 net loss $3.6M; cash $0.7M; Phase 3 trial 50% enrolled; strategic review underway
Ensysce Biosciences, Inc.
2026-Q1 EPS reported
-$0.52
revenue$960,999
- Net loss attributable to common stockholders $3.6M vs $1.9M in Q1 2025; R&D expense rose to $3.3M on Phase 3 costs.
- Cash and equivalents $0.7M at March 31, 2026; subsequent $2.0M convertible preferred financing closed April 7.
- Achieved 50% of interim enrollment target in pivotal PF614-301 Phase 3 trial for moderate to severe pain.
- IRB approval secured for Part 3 of PF614-MPAR-102; first peer-reviewed MPAR data published in Journal of Opioid Management.
- Board initiated formal review of strategic alternatives, including partnerships and licensing opportunities.
item 2.02item 9.01